Press Releases Genovis AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:37 2024-05-24 am EDT			5-day change	1st Jan Change
33.9 ^SEK	-4.10%		+0.30%	-34.81%

May. 15	Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 14	Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement	CI

GenovisQ1 2024 - Financials in line with expectations, strong outlook	May. 16	AQ
Interim Report January - March 2024	May. 15	AQ
Genovis Annual Report 2023 published	Apr. 24	AQ
NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING	Apr. 09	AQ
Carthesian Therapeutics terminates Genovis Licence Agreement	Mar. 14	AQ
Genovis Q4 2023 - Soft ending but promising start	Feb. 19	AQ
Year-end report January-December 2023	Feb. 15	AQ
Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme	Feb. 13	AQ
Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
Genovis Q3 2023 - Solid growth and profitability, Xork timeline remains on track	Nov. 16	AQ
Genovis Q2 2023 - Strong growth and expanding EBIT margin	23-08-25	AQ
Half-Yearly Report January-June 2023	23-08-24	AQ
Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets	23-06-02	AQ
Genovis Q1 2023 - Strongest report to date	23-05-17	AQ
Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023	23-05-16	AQ
Interim Report January-March 2023	23-05-16	AQ
ArcticZymes Technologies and Genovis enter into a collaboration agreement to accelerate growth in China.	23-05-03	AQ
Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China	23-05-03	AQ
Genovis acquires IP Rights to novel enzymes for applications within genomics	23-04-25	AQ
Genovis Annual Report 2022 published	23-04-25	AQ

No results for this search